Summary: Until now, chronic traumatic encephalopathy could only be diagnosed post-mortem. Researchers have identified a potential biomarker that could help diagnose CTE during a person’s lifetime.
Source: Boston University School of Medicine.
A new biomarker (CCL11) for chronic traumatic encephalopathy (CTE) has been discovered that may allow the disease to be diagnosed during life for the first time.
The findings, which appear in the journal PLOS ONE, might also help distinguish CTE from Alzheimer’s disease, which often presents with symptoms similar to CTE and also can only be diagnosed post-mortem. The ability to diagnose CTE in living individuals will allow for research into prevention and treatment of the disease.
Researchers from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System (VABHS) studied the brains of 23 former college and professional football players. They compared them to the brains of 50 non-athletes with Alzheimer’s disease and 18 non-athlete controls.
They observed that CCL11 levels were normal in the brains of the non-athlete controls and non-athletes with Alzheimer’s disease, but were significantly elevated in the brains of individuals with CTE. They then compared the degree of elevation of CCL11 to the number of years those individuals played football and found that there was a positive correlation between the CCL11 levels and the number of years played.
The researchers also took post-mortem samples of the cerebrospinal fluid (CSF) from four of the control individuals, seven of the individuals with CTE and four of the individuals with Alzheimer’s disease, and found that CCL11 levels in the CSF were similarly normal in the control and Alzheimer’s individuals, but elevated in those individuals with CTE, suggesting that the presence of CCL11 in the CSF might be able to assist in the detection of CTE during life.
“Not only did this research show the potential for CTE diagnosis during life, but it also offers a possible mechanism for distinguishing between CTE and other diseases. By making it possible to distinguish between normal individuals, individuals with Alzheimer’s disease, and CTE therapies can become more targeted and hopefully more effective,” explained first author Jonathan Cherry, PhD, postdoctoral fellow in neurology at BUSM.
“The findings of this study are the early steps toward identifying CTE during life. Once we can successfully diagnose CTE in living individuals, we will be much closer to discovering treatments for those who suffer from it,” said senior author Ann McKee, MD, Director of BU’s CTE Center and Chief of Neuropathology at VABHS.
Future studies are needed to determine whether increased levels of CCL11 are an early or late finding in the CTE disease process and whether CCL11 levels might be able to predict the severity of an individual’s disease.
CTE is a progressive degenerative disease of the brain found in athletes and others with a history of repetitive brain trauma, including symptomatic concussions as well as asymptomatic sub-concussive hits to the head. Although the incidence and prevalence of CTE is unknown, it has been diagnosed in former amateur and professional contact sport athletes as well as military veterans. Given the millions of contact sport athletes and military service members exposed to repetitive head impacts each year, CTE has become a major public health concern.
About this neuroscience research article
Funding: Funding for this study was provided by the Department of Veterans Affairs, Veterans Health Administration, Clinical Sciences Research and Development Merit Award (I01-CX001038); Alzheimer’s Association (NIRG-305779); Veterans Affairs Biorepository (CSP 501); National Institute of Aging (1RF1AG054156-01); National Institute of Aging Boston University AD Center (P30AG13846; supplement 0572063345-5); Department of Defense Peer Reviewed Alzheimer’s Research Program (DoD-PRARP #13267017); National Heart, Lung, and Blood Institute, Framingham Heart Study, (NHLBI/NIH #N01-HC-25195 and R01AG08122 ); NINDS (1F32NS096803-01); Concussion Legacy Foundation. This work was also supported by unrestricted gifts from the Andlinger Foundation and WWE.
Source: Gina DiGravio – Boston University School of Medicine Image Source: NeuroscienceNews.com image is in the public domain. Original Research: Full open access research for “CCL11 is increased in the CNS in chronic traumatic encephalopathy but not in Alzheimer’s disease” by Jonathan D. Cherry, Thor D. Stein, Yorghos Tripodis, Victor E. Alvarez, Bertrand R. Huber, Rhoda Au, Patrick T. Kiernan, Daniel H. Daneshvar, Jesse Mez, Todd M. Solomon, Michael L. Alosco, and Ann C. McKee in PLOS ONE. Published online September 26 2017 doi:10.1371/journal.pone.0185541
Cite This NeuroscienceNews.com Article
[cbtabs][cbtab title=”MLA”]Boston University School of Medicine “Biomarker May Help Diagnose CTE During Life.” NeuroscienceNews. NeuroscienceNews, 30 September 2017. <https://neurosciencenews.com/cte-biomarker-7626/>.[/cbtab][cbtab title=”APA”]Boston University School of Medicine (2017, September 30). Biomarker May Help Diagnose CTE During Life. NeuroscienceNews. Retrieved September 30, 2017 from https://neurosciencenews.com/cte-biomarker-7626/[/cbtab][cbtab title=”Chicago”]Boston University School of Medicine “Biomarker May Help Diagnose CTE During Life.” https://neurosciencenews.com/cte-biomarker-7626/ (accessed September 30, 2017).[/cbtab][/cbtabs]
CCL11 is increased in the CNS in chronic traumatic encephalopathy but not in Alzheimer’s disease
CCL11, a protein previously associated with age-associated cognitive decline, is observed to be increased in the brain and cerebrospinal fluid (CSF) in chronic traumatic encephalopathy (CTE) compared to Alzheimer’s disease (AD). Using a cohort of 23 deceased American football players with neuropathologically verified CTE, 50 subjects with neuropathologically diagnosed AD, and 18 non-athlete controls, CCL11 was measured with ELISA in the dorsolateral frontal cortex (DLFC) and CSF. CCL11 levels were significantly increased in the DLFC in subjects with CTE (fold change = 1.234, p < 0.050) compared to non-athlete controls and AD subjects with out a history of head trauma. This increase was also seen to correlate with years of exposure to American football (β = 0.426, p = 0.048) independent of age (β = -0.046, p = 0.824). Preliminary analyses of a subset of subjects with available post-mortem CSF showed a trend for increased CCL11 among individuals with CTE (p = 0.069) mirroring the increase in the DLFC. Furthermore, an association between CSF CCL11 levels and the number of years exposed to football (β = 0.685, p = 0.040) was observed independent of age (β = -0.103, p = 0.716). Finally, a receiver operating characteristic (ROC) curve analysis demonstrated CSF CCL11 accurately distinguished CTE subjects from non-athlete controls and AD subjects (AUC = 0.839, 95% CI 0.62–1.058, p = 0.028). Overall, the current findings provide preliminary evidence that CCL11 may be a novel target for future CTE biomarker studies.
“CCL11 is increased in the CNS in chronic traumatic encephalopathy but not in Alzheimer’s disease” by Jonathan D. Cherry, Thor D. Stein, Yorghos Tripodis, Victor E. Alvarez, Bertrand R. Huber, Rhoda Au, Patrick T. Kiernan, Daniel H. Daneshvar, Jesse Mez, Todd M. Solomon, Michael L. Alosco, and Ann C. McKee in PLOS ONE. Published online September 26 2017 doi:10.1371/journal.pone.0185541